Market Overview

ROVIDIUM Ready to Hit the Market, Dr. Chunyu Zhang's Anti-Cancer and Anti-Aging Results Delivered

Share:

Both luxury and core versions of the novel dietary supplement ROVIDIUM
for anti-cancer and anti-aging effects, have been approved by the US
Food and Drug Administration (FDA) and obtained Certificates of Free
Sale. ROVIDIUM is based on the latest research from Dr. Chunyu Zhang,
Principal Investigator for the Lung Cancer and Aging Program at the
Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University
School of Medicine. The product is soon to meet clients in both the US
and China.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180725005385/en/

Figure illustrating Luxury Version and Core Version of ROVIDIUM products customized for different gr ...

Figure illustrating Luxury Version and Core Version of ROVIDIUM products customized for different groups of people (Photo: Business Wire)

ROVIDIUM contains core ingredients of rice germ and rice bran extract
Ceramide, turmeric extract Curcumin and green tea extract EGCG, with raw
materials selected from Japan, Germany, China and US brand suppliers.
The ingredients are evaluated by the US FDA as "Generally Recognized as
Safe" (GRAS). Purified by high-tech and micro-encapsulated, ROVIDIUM
features excellent purity, sustained-release stability and
bioavailability. The production and packaging will take place in
California in accordance with the cGMP standard and above.

Although ROVIDIUM has yet to be officially released, its design concept
of both anti-cancer and anti-aging biological effects and food-grade
natural ingredients have caught the eyes of the US media. Additionally,
with the ever growing demand for self-health management, the exploration
and respect for natural ingredients is a continuing trend in the health
market industry. Therefore, ROVIDIUM comes into being at the right time.

Dr. Chunyu Zhang, the developer of ROVIDIUM, remarked, "The Nobel
laureate Dr. James Watson, who is one of the co-discoverers of the DNA
double helix in 1953 with Francis Crick and Rosalind Franklin, mentioned
in his speech on cancer treatment at the Shenzhen Precision Medicine
Summit last year that since the targeted therapy based on gene mutation
needs to be improved and immunotherapy is unaffordable for average
families, the search for safe, effective and affordable anti-cancer
substances from natural products will benefit more people and should be
the direction for future."

To date, the prevention and treatment of cancer remain major problems
facing all countries around the world. Due to its high treatment cost
and severe toxic side effects of radiotherapy and chemotherapy, cancer
has been a nightmare to all. The common practice for cancer prevention
is genetic screening and vaccination. Although effective, effects are
limited. Genetic screening is only a projection of probability, and
vaccines can only cover a few types of cancer. For high incidence
cancers such as lung cancer, there is currently no vaccine.

"There is no doubt that cancer prevention is the smartest investment and
the most economical way of treatment," said Dr. Chunyu Zhang.

Through years of research on cancer and aging, Dr. Zhang found that
cancer and aging are inextricably linked to each other. As aging
increases the number of DNA replication and cell division, DNA damage
inevitably accumulates, resulting in cell aging and failure, hence the
formation of cancer cells increases and the body keeps losing control of
them. In the research process of the lung cancer and aging project, Dr.
Chunyu Zhang found that cancer prevention and anti-aging can be both
achieved by using the targeting cell growth signal pathway and reducing
DNA damage accumulation and eliminating chronic inflammation.

In the end, Dr. Zhang Chunyu found a tumor suppressor gene that is
constantly down-regulated by epigenetics during aging and canceration.
Through the bioinformatics analysis of the transcriptional factor
binding siteson its promoter DNA sequence, as well as the binding site
mutation or deletion experiments, an entire new molecular mechanism and
related signaling pathway for efficient transcriptional activation of
the tumor suppressor gene was discovered. Through rigorous scientific
experiments, Dr. Zhang has proven that its rapid induction is due to not
only the blockage of the signal path that promotes growth, but also the
trigger of the signal path that inhibits growth. Just like a
fast-running car, it can only be stopped when both the throttle and the
brakes are closed. Moreover, Dr. Zhang further proved that highly
malignant cancer cells no longer tolerate the expression recovery of the
tumor suppressor gene, leading to inhibition of cell proliferation and
migration, and programmed cell suicide. Therefore, the re-expression of
the tumor suppressor gene is a biomarker for blocking the growth and
metastasis of cancer cells, and is also an effector molecule that
promotes apoptosis.

Accordingly, Dr. Zhang Chunyu further constructed the world's unique
dual-fluorescein single-molecule vector driven by the tumor suppressor
gene, and screened out novel anti-cancer small molecules from The NCI
Diversity Set II Compound Library.

After finding the "key" to the problem, Dr. Chunyu Zhang started to
search for ingredients globally and configured phytonutrients. "Compared
with chemically synthetic substances that do not exist in nature for
countering the risk of cancer, it is better to find safer
chemopreventive small molecules from natural products to effectively
intervene with cancer cell proliferation and survival pathways," Dr.
Zhang said.

Through in-depth research, Dr. Chunyu Zhang not only discovered the
natural plant small molecules that can reconstitute the tumor suppressor
gene in cancer cells, but also found a combination of plant compounds
that can elevate the level of the protein in normal cells. Dr. Zhang is
currently submitting American and PCT patent application about the
composition of these phytonutrients to slow down the normal cell aging
process and decrease cancer cell formation. These discoveries led to the
production of ROVIDIUM.

"Now we are at the final stage to prepare ROVIDIUM for the market, and
we have designed both core and luxury versions for different groups of
people. It is expected to meet consumers in August," added Dr. Chunyu
Zhang.

View Comments and Join the Discussion!